Trial Title:
Cevostamab Following CAR T Cell Therapy for RRMM
NCT ID:
NCT05801939
Condition:
Relapsed/Refractory Multiple Myeloma
Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Cevostamab
Description:
Cevostamab will be given as an IV infusion once every 3 weeks, starting roughly 10 weeks
(day 70 +/- 4 days) post-CAR T cell infusion, with subjects planned to receive 8 cycles
initially. Subjects receive a single step-up dose of 3.6 mg of cevostamab on cycle 1, day
1 (C1D1), followed by the recommended target dose (160 mg, 132mg, or 90 mg based on
results of safety run-in data and safety review) on C1D8. Myeloma responses are assessed
every cycle, and a repeat bone marrow aspirate and biopsy (BMbx) is performed at the
start of cycle 8. If participants are not in an MRD-negative CR at this timepoint (or if
the BM bx is inevaluable/indeterminate for CR or MRD testing), they continue with another
8 cycles (C9-16) of cevostamab. If they are in MRD-negative CR at start of C8, they stop
therapy after receiving this cycle and are observed.
Arm group label:
Cevostamab
Summary:
This is a Phase 2, open-label, single-arm, single stage, single-institution study, with
an initial safety run-in period. Potential participants with relapsed/refractory myeloma
who are undergoing standard of care, commercially-available BCMA-directed CAR T cell
therapy may be identified pre-CAR T cell infusion but are not consented and enrolled
until at least 4-6 weeks after CAR T cell infusion, once recovered from acute toxicities.
Note: the lymphodepleting chemotherapy and CAR T cell therapy is being administered as
part of standard clinical practice and is not considered part of this protocol.
Alternative lymphodepleting regimens other than fludarabine and cyclophosphamide (eg in
the setting of fludarabine shortages) are acceptable. Cevostamab will be given as an IV
infusion once every 3 weeks, starting roughly 10 weeks (day 70 +/- 4 days) post-CAR T
cell infusion, with subjects planned to receive 8 cycles initially. Aiming to assess the
impact of cevostamab consolidation post-BCMA CAR T cell therapy on rate of MRD-negative
complete remission (CR) at 12 months.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Signed Informed Consent Form(s)
2. Age ≥18 years at time of signing Informed Consent Form
3. Ability to comply with the study protocol
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
5. Life expectancy of at least 12 weeks
6. Participants must have relapsed and/or refractory multiple myeloma with therapy that
must include a proteasome inhibitor, immunomodulatory drug (IMiD), and anti-CD38
antibody, and have received a BCMA-directed CAR T cell product as standard of care
(i.e. not on a clinical trial) as per the current FDA label, between 6 and 10 weeks
prior to enrollment, and have not had progressive disease by IMWG criteria since CAR
T cell infusion. Patients who have received out-of-specification CAR T cell products
are not eligible.
1. For patients who received ide-cel, they must have had at least 2 prior lines of
therapy prior to ide-cel
2. For patients who received cilta-cel, they must have had at least 2 prior lines
prior to cilta-cel, or 1 prior line and be refractory or intolerant to
lenalidomide.
7. Agreement to provide bone marrow biopsy and aspirate samples
8. Non-hematologic adverse events from prior anti-cancer therapy resolved to Grade ≤ 1,
with the certain exceptions.
9. Measurable disease is not required for study entry
10. Laboratory values as follows:
a. Hepatic function i. AST and ALT ≤ 3 x ULN ii. Total bilirubin ≤ 1.5 x ULN; b.
Hematologic function (cevostamab criteria should be met both at screening (to
determine eligibility), as well as on Cycle1, Day 1) i. Platelet count ≥ 50,000/mm3
without transfusion within 7 days prior to first dose ii. ANC ≥ 1000/mm3 iii. Total
hemoglobin ≥ 7 g/dL c. Creatinine clearance (CrCl) ≥ 30 mL/min d. Serum calcium
(corrected for albumin) level at or below Grade 1 hypercalcemia
11. For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive measures, as defined in the protocol.
12. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or
use a condom, and agreement to refrain from donating sperm, as defined in the
protocol.
Exclusion Criteria:
1. Inability to comply with protocol-mandated hospitalization and activities
restrictions
2. Pregnant or breastfeeding, or intending to become pregnant during the study or
within 3 months after the last dose of study drug
a. Women of childbearing potential must have a negative serum pregnancy test result
within 14 days prior to initiation of study drug.
3. Participants who had ≥ Grade 3 cytokine release syndrome (CRS) or immune effector
cell-associated neurotoxicity syndrome (ICANS) by ASTCT criteria, or any grade
macrophage activation syndrome/hemophagocytic lymphohistiocytosis (MAS/HLH)after
CAR-T therapy are excluded
4. Participants who had any grade movement and/or neurocognitive disorder attributed to
CAR T cells are excluded.
5. Prior treatment with systemic immunotherapeutic agents, including, but not limited
to, cytokine therapy and anti-CTLA4, anti-PD-1, and anti-PD-L1 therapeutic
antibodies, within 12 weeks or 5 half-lives of the drug, whichever is shorter,
before first cevostamab infusion
6. Known treatment-related, immune-mediated adverse events associated with prior
immunotherapeutic agents as in the protocol.
7. Treatment with any chemotherapeutic agent, or any other anti-cancer agent
(investigational or otherwise) during the time period between CAR T cell infusion
and first cevostamab infusion, with the following exceptions:
1. Therapies used for treatment of CAR T cell-related toxicities (e.g. steroids,
cyclophosphamide) will not be a cause for exclusion, as long as washout period
listed below (2 weeks) is met
2. Short course palliative radiation post-CAR T cell therapy (e.g. for severe bone
pain, impending fracture) is allowed as long as completed at least 1 week prior
to first dose of cevostamab.
8. Received systemic immunosuppressive medications (including, but not limited to,
steroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, tocilizumab,
siltuximab, anakinra, ruxolitinib, and anti-tumor necrosis factor agents), with the
exception of corticosteroid treatment ≤ 10 mg/day prednisone or equivalent, within 2
weeks prior to first dose of cevostamab
a. Participants who received acute, low-dose, systemic immunosuppressant medications
(e.g., single dose of dexamethasone for nausea) may be enrolled in the study.
i. The use of inhaled corticosteroids is permitted. ii. The use of
mineralocorticoids for management of orthostatic hypotension is permitted.
iii. The use of physiologic doses of corticosteroids for management of adrenal
insufficiency is permitted.
9. Autologous stem cell transplantation (SCT) within 100 days prior to first cevostamab
infusion
10. Prior allogeneic SCT within 12 months prior to first cevostamab infusion.
Participants with prior allogeneic SCT must have no evidence for active
graft-versus-host-disease (GVHD) and be off all therapy for GVHD for at least 3
months prior to first cevostamab infusion.
11. Prior solid organ transplantation
12. History of autoimmune disease, including, but not limited to, myasthenia gravis,
myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
multiple sclerosis, vasculitis, or glomerulonephritis
1. Participants with a history of autoimmune-related hypothyroidism on a stable
dose of thyroid replacement hormone may be eligible for this study.
2. Participants with history of immune thromobocytopenic purpura (ITP), autoimmune
hemolytic anemia, or other immune-mediated conditions that solely affect blood
counts, as long as these conditions are not active at the time of enrollment
and subjects otherwise meet hematologic parameters for eligibility, may be
eligible with approval from Sponsor Medical Director.
13. Participants with history of confirmed progressive multifocal leukoencephalopathy
14. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
(or recombinant antibody-related fusion proteins)
15. History of other malignancy that could affect compliance with the protocol or
interpretation of results
1. Participants with a history of curatively treated basal or squamous cell
carcinoma of the skin or in situ carcinoma of the cervix are allowed.
2. Participants with a malignancy that has been treated with curative intent will
also be allowed if the malignancy has been in remission prior to first
cevostamab infusion.
16. Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis,
neurodegenerative disease, or CNS involvement by MM
1. Participants with a history of stroke who have not experienced a stroke or
transient ischemic attack in the past 2 years and have no residual neurologic
deficits as judged by the investigator are allowed.
2. Participants with a history of epilepsy who have had no seizures in the past 2
years while not receiving any anti-epileptic medications are allowed.
17. Significant cardiovascular disease (such as, but not limited to, New York Heart
Association Class III or IV cardiac disease, myocardial infarction within the last 6
months, uncontrolled arrhythmias, or unstable angina) that may limit a subject's
ability to adequately tolerate a cytokine release syndrome (CRS) event
18. Symptomatic active pulmonary disease or requiring supplemental oxygen
19. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
(excluding fungal infections of nail beds) at study enrollment, or any major episode
of infection requiring treatment with IV antibiotics within 14 days prior to first
cevostamab infusion. Empiric or prophylactic antibiotics administered during
neutropenia or neutropenic fever without microbiologic evidence of infection do not
exclude subjects.
a. Participants with asymptomatic CMV reactivation (i.e. positive CMV PCR) found at
screening may enroll after discussion with the Medical Director.
20. Known or suspected chronic active Epstein-Barr virus (EBV) infection. Guidelines for
diagnosing chronic active EBV infection are provided by Okano et al. (2005).
21. Recent major surgery within 4 weeks prior to first cevostamab infusion
a. Protocol-mandated procedures (e.g., bone marrow biopsies) are permitted.
22. Positive serologic or polymerase chain reaction (PCR) test results for acute or
chronic hepatitis B virus (HBV) infection
a. Participants whose HBV infection status cannot be determined by serologic test
results must be negative for HBV by PCR to be eligible for study participation.
23. Acute or chronic hepatitis C virus (HCV) infection
a. Participants who are positive for HCV antibody must be negative for HCV by PCR to
be eligible for study participation.
24. Known history of HIV seropositivity
25. Administration of a live, attenuated vaccine within 4 weeks before first cevostamab
infusion or anticipation that such a live attenuated vaccine will be required during
the study
1. Influenza vaccination should be given during influenza season (approximately
October to May in the Northern Hemisphere). Subjects must not receive live,
attenuated influenza vaccine (e.g., FluMist®) at any time during the study
treatment period.
2. SARS-CoV-2 vaccines may be given in accordance with the approved/authorized
vaccine label and official/local immunization guidance. SARS-CoV-2 vaccines
must not be administered within 1 week before first study treatment or during
Cycle 1.
3. Investigators should review the vaccination status of potential study subjects
being considered for this study and follow the U.S. Centers for Disease Control
and Prevention guidelines for adult vaccination with any other non-live
vaccines intended to prevent infectious diseases prior to study.
26. Any medical condition or abnormality in clinical laboratory tests that, in the
Medical Director's judgment, precludes the subject's safe participation in and
completion of the study, or which could affect compliance with the protocol or
interpretation of results.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Hospital of the University of Pennsylvania
Address:
City:
Philadelphia
Zip:
19104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Sara Whittington
Phone:
215-220-9688
Email:
Sara.Whittington@pennmedicine.upenn.edu
Start date:
July 11, 2023
Completion date:
May 2028
Lead sponsor:
Agency:
University of Pennsylvania
Agency class:
Other
Collaborator:
Agency:
Genentech, Inc.
Agency class:
Industry
Source:
University of Pennsylvania
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05801939
